FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983804536> ?p ?o ?g. }

• W2983804536 endingPage "2588" @default.
• W2983804536 startingPage "2588" @default.
• W2983804536 abstract "Introduction Novel high-risk groups have been identified in adult ALL, including secondary (sALL) and Philadelphia-like ALL (Ph-like, based on CRLF2, IgH, ABL2, JAK2 and other tyrosine kinase translocations), and those with minimal residual disease >0.1% (MRD+) after induction therapy. Novel targeted therapies are now routinely incorporated into 1st line regimens, including tyrosine kinase inhibitors (BCR-ABL1-pos), rituximab (CD20+) and blinatumomab (Blina) for MRD+. The impact of these novel high risk groups and therapies after alloHCT is unknown; therefore, we evaluated their impact on overall survival (OS), relapse rate (REL), non-relapse mortality (NRM) and acute and chronic GVHD. Methods We evaluated pts receiving 1st Allo-HCT for ALL at Mayo Clinic (Rochester, Phoenix, and Jacksonville) from 2008-2018 for outcomes of interest, specifically the impact of novel therapies and risk groups. Associations of patient factors with outcomes were examined using univariable (UVA) and multivariable (MVA) Cox proportional hazards regression models, where the cause-specific hazard of the given outcome was modeled to account for the competing risk of death. Results We identified 261 consecutive AlloHCT recipients during the study period. Median age at transplant was 48 years (18-72) and 147 (56.3%) were male. The median comorbidity (HCT-CI) score was 2 (0-8). 213 pts (81.6%) had B-lineage ALL, of which 85 (32.6%) were BCR-ABL-pos, 17 (6.5%) Ph-like (identified by FISH), 16 (6.1%) hypoploidy/near triploidy (Hy/Tri), and 67 (25.7%) pre-B ALL NOS. The remaining 48 (18.4%) had T-ALL. 30 pts (11.5%) had sALL (i.e. prior chemo/radiotherapy for another malignancy). HyperCVAD was the most common 1st line regimen (68.2%). 243 (93.1%) pts achieved Complete Remission (CR1) after induction therapy, and 203 (77.8%) were in CR1 at the time of alloHCT. Blina was administered for MRD+ in 14 pts (5.4%), and for relapsed/refractory ALL (R/R) in 13 (27% of R/R pts), 7 of whom received Blina as initial therapy for R/R. Donors were matched unrelated in 149 (57.1%), matched related in 98 (37.5%), and haploidentical in 14 (5.4%). Peripheral blood (PB) grafts were used in 233 (89.3%). 103 (54.5%) were donor:recipient (D:R) sex-matched, and 86 D:R mismatched [47 (24.9%) M:F; and 39 (20.6%) F:M]. Myeloablative conditioning was used for the majority (78.5%) mostly with Cy/TBI (60.5%). Standard GVHD prophylaxis regimens were used. Outcomes Median follow-up after transplant was 22.4 months (0.5-135), and 51 (19.5%) had REL. The 1, 2 and 5-year survival rates were 71.9%, 64.9%, and 54.1%, respectively (Figure 1). Acute GVHD developed in 144 (55.2%) and chronic GVHD in 100 (38.3%). Ph-like ALL, Blina for MRD+, Blina for R/R, sALL and CD20-pos had no independent impact on OS. In contrast, age>60, Hy/Tri, and >CR1 at alloHCT were associated with worse OS in UVA, however, in MVA only pre-B ALL NOS was associated with better OS. Female:male D:R status was associated with inferior OS. Blina for R/R disease was associated with increased risk of REL in UVA [HR 5.26 95% CI (1.33, 20.00), p=0.017], whereas other novel high risk groups had no impact on REL. In contrast, T-ALL, Hy/Tri and >CR1 at AlloHCT were associated with increased REL in UVA, but only T-ALL and Hy/Tri continued to predict for increased REL in MVA. Secondary ALL was associated with increased NRM in UVA [HR 1.96 95% CI (1.07, 3.57), p=0.028], whereas other novel high risk groups had no impact on NRM. In contrast, age>60, >CR1 at AlloHCT and D:R sex mismatch were associated with higher NRM in UVA, but only sex mismatch and >CR1 at AlloHCT were associated with higher NRM in MVA. TBI use was associated with higher risk of acute GvHD (p=0.008) and ATG use with lower risk chronic GVHD (p<0.001). Similarly non-PB grafts were associated with a lower risk of chronic GVHD (p=0.005). Results for OS, REL, NRM, acute and chronic GVHD analysis are shown in Table 1. Conclusion Novel high risk groups (CD20+, Ph-like and sALL) do not appear to adversely impact OS after alloHCT, although sALL was associated with increased risk of NRM. Interestingly, pre-B-ALL NOS appear to be associated with favorable OS. Novel targeted therapies also do not independently predict outcome, with the exception of Blina for R/R ALL which may be associated with REL after subsequent alloHCT (a subgroup for whom novel maintenance strategies should be explored). Our analysis highlights the importance of allo-HCT for novel high risk ALL subgroups. Disclosures Patnaik: Stem Line Pharmaceuticals.: Membership on an entity's Board of Directors or advisory committees. Kharfan-Dabaja:Daiichi Sankyo: Consultancy; Pharmacyclics: Consultancy. Foran:Agios: Honoraria, Research Funding." @default.
• W2983804536 created "2019-11-22" @default.
• W2983804536 creator A5000881706 @default.
• W2983804536 creator A5017327825 @default.
• W2983804536 creator A5021941594 @default.
• W2983804536 creator A5031027678 @default.
• W2983804536 creator A5035051206 @default.
• W2983804536 creator A5049552841 @default.
• W2983804536 creator A5055281451 @default.
• W2983804536 creator A5064856519 @default.
• W2983804536 creator A5069106464 @default.
• W2983804536 creator A5072463255 @default.
• W2983804536 creator A5073183082 @default.
• W2983804536 creator A5084606047 @default.
• W2983804536 creator A5085360755 @default.
• W2983804536 creator A5089383415 @default.
• W2983804536 creator A5091287816 @default.
• W2983804536 date "2019-11-13" @default.
• W2983804536 modified "2023-09-30" @default.
• W2983804536 title "Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort" @default.
• W2983804536 doi "https://doi.org/10.1182/blood-2019-122068" @default.
• W2983804536 hasPublicationYear "2019" @default.
• W2983804536 type Work @default.
• W2983804536 sameAs 2983804536 @default.
• W2983804536 citedByCount "0" @default.
• W2983804536 crossrefType "journal-article" @default.
• W2983804536 hasAuthorship W2983804536A5000881706 @default.
• W2983804536 hasAuthorship W2983804536A5017327825 @default.
• W2983804536 hasAuthorship W2983804536A5021941594 @default.
• W2983804536 hasAuthorship W2983804536A5031027678 @default.
• W2983804536 hasAuthorship W2983804536A5035051206 @default.
• W2983804536 hasAuthorship W2983804536A5049552841 @default.
• W2983804536 hasAuthorship W2983804536A5055281451 @default.
• W2983804536 hasAuthorship W2983804536A5064856519 @default.
• W2983804536 hasAuthorship W2983804536A5069106464 @default.
• W2983804536 hasAuthorship W2983804536A5072463255 @default.
• W2983804536 hasAuthorship W2983804536A5073183082 @default.
• W2983804536 hasAuthorship W2983804536A5084606047 @default.
• W2983804536 hasAuthorship W2983804536A5085360755 @default.
• W2983804536 hasAuthorship W2983804536A5089383415 @default.
• W2983804536 hasAuthorship W2983804536A5091287816 @default.
• W2983804536 hasConcept C126322002 @default.
• W2983804536 hasConcept C143998085 @default.
• W2983804536 hasConcept C207103383 @default.
• W2983804536 hasConcept C2777408962 @default.
• W2983804536 hasConcept C2778020697 @default.
• W2983804536 hasConcept C2778461978 @default.
• W2983804536 hasConcept C2779338263 @default.
• W2983804536 hasConcept C2779823535 @default.
• W2983804536 hasConcept C2780653079 @default.
• W2983804536 hasConcept C2909962599 @default.
• W2983804536 hasConcept C2911091166 @default.
• W2983804536 hasConcept C44249647 @default.
• W2983804536 hasConcept C50382708 @default.
• W2983804536 hasConcept C71924100 @default.
• W2983804536 hasConceptScore W2983804536C126322002 @default.
• W2983804536 hasConceptScore W2983804536C143998085 @default.
• W2983804536 hasConceptScore W2983804536C207103383 @default.
• W2983804536 hasConceptScore W2983804536C2777408962 @default.
• W2983804536 hasConceptScore W2983804536C2778020697 @default.
• W2983804536 hasConceptScore W2983804536C2778461978 @default.
• W2983804536 hasConceptScore W2983804536C2779338263 @default.
• W2983804536 hasConceptScore W2983804536C2779823535 @default.
• W2983804536 hasConceptScore W2983804536C2780653079 @default.
• W2983804536 hasConceptScore W2983804536C2909962599 @default.
• W2983804536 hasConceptScore W2983804536C2911091166 @default.
• W2983804536 hasConceptScore W2983804536C44249647 @default.
• W2983804536 hasConceptScore W2983804536C50382708 @default.
• W2983804536 hasConceptScore W2983804536C71924100 @default.
• W2983804536 hasIssue "Supplement_1" @default.
• W2983804536 hasLocation W29838045361 @default.
• W2983804536 hasOpenAccess W2983804536 @default.
• W2983804536 hasPrimaryLocation W29838045361 @default.
• W2983804536 hasRelatedWork W2483118035 @default.
• W2983804536 hasRelatedWork W2538699508 @default.
• W2983804536 hasRelatedWork W2787145330 @default.
• W2983804536 hasRelatedWork W2790784493 @default.
• W2983804536 hasRelatedWork W2912405408 @default.
• W2983804536 hasRelatedWork W2952590487 @default.
• W2983804536 hasRelatedWork W2955874201 @default.
• W2983804536 hasRelatedWork W4207025016 @default.
• W2983804536 hasRelatedWork W4281551859 @default.
• W2983804536 hasRelatedWork W4321785464 @default.
• W2983804536 hasVolume "134" @default.
• W2983804536 isParatext "false" @default.
• W2983804536 isRetracted "false" @default.
• W2983804536 magId "2983804536" @default.
• W2983804536 workType "article" @default.